|
|
Abbott Laboratories (ABT) |
|
|
|
| |
ABT's Capital Expenditures Growth by Quarter and Year
Abbott Laboratories's Capital Expenditures results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
| ABT Capital Expenditures (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
610.00
|
614.00
|
679.00
|
| III Quarter |
September |
-
|
467.00
|
461.00
|
496.00
|
| II Quarter |
June |
507.00
|
379.00
|
413.00
|
642.00
|
| I Quarter |
March |
380.00
|
321.00
|
397.00
|
360.00
|
| FY |
|
887.00
|
1,777.00
|
1,885.00
|
2,177.00
|
| ABT Capital Expenditures second quarter 2023 Y/Y Growth Comment |
Abbott Laboratories achieved in the second quarter 2023, above Company average Capital Expenditures growth of 33.77% year on year, to $ 507.00 millions.
Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Capital Expenditures growth. While Abbott Laboratories' s Capital Expenditures rise of 33.77% ranks overall at the positon no. 1102 in the second quarter 2023.
|
| ABT Capital Expenditures ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-0.65 % |
-9.57 % |
56.45 % |
| III Quarter |
September |
- |
1.3 % |
-7.06 % |
23.69 % |
| II Quarter |
June |
33.77 % |
-8.23 % |
-35.67 % |
37.18 % |
| I Quarter |
March |
18.38 % |
-19.14 % |
10.28 % |
7.46 % |
| FY |
|
- |
-5.73 % |
-13.41 % |
32.91 % |
ABT Capital Expenditures (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
30.62 % |
33.19 % |
36.9 % |
| III Quarter |
September |
- |
23.22 % |
11.62 % |
-22.74 % |
| II Quarter |
June |
33.42 % |
18.07 % |
4.03 % |
78.33 % |
| I Quarter |
March |
-37.7 % |
-47.72 % |
-41.53 % |
-17.05 % |
| FY (Year on Year) |
|
- |
-5.73 % |
-13.41 % |
32.91 % |
| Capital Expenditures Y/Y Growth Statistics |
| High |
Average |
Low |
| 68.12 % |
1.39 % |
-100 % |
| (Sep. 30, 2011) |
|
(Dec 31 2011) |
|
|
| Capital Expenditures Y/Y Growth Statistics |
| High |
Average |
Low |
| 68.12 % |
1.39 % |
-100 % |
| (Sep. 30, 2011) |
|
(Dec 31 2011) |
|
| Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Abbott Laboratories's Q/Q Capital Expenditures Growth
| Capital Expenditures Q/Q Growth Statistics |
| High |
Average |
Low |
| 111.57 % |
6.94 % |
-100 % |
| (June 30. 2010) |
|
|
| ABT's II. Quarter Q/Q Capital Expenditures Comment |
Abbott Laboratories achieved in the II. Quarter 2023 above company average sequential Capital Expenditures jump of 33.42%, to $ 507.00 millions, from $380.00 millions in the first quarter.
Major Pharmaceutical Preparations company is impressively improving, with reporting above regular increase, and also increasing speed.
Within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 394. |
|
|
|
| Capital Expenditures Q/Q Growth Statistics |
| High |
Average |
Low |
| 111.57 % |
6.94 % |
-100 % |
| (June 30. 2010) |
|
|
| ABT's II. Quarter Q/Q Capital Expenditures Comment |
Abbott Laboratories achieved in the II. Quarter 2023 above company average sequential Capital Expenditures jump of 33.42%, to $ 507.00 millions, from $380.00 millions in the first quarter.
ABT is going from strength to strength, not only recording higher then average gain, and additionally increasing pace.
Within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 394. |
|
Abbott Laboratories's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
| Cumulative Capital Expenditures 12 Months Ending |
$ 1,964.00 |
$ 1,836.00 |
$ 1,777.00 |
$ 1,781.00 |
$ 1,775.00 |
| Y / Y Capital Expenditures Growth (TTM) |
10.65 % |
1.49 % |
-5.73 % |
-8.67 % |
-10.58 % |
| Year on Year Capital Expenditures Growth Overall
Ranking |
# 902 |
# 857 |
# 1750 |
# 1866 |
# 743 |
| Seqeuential Capital Expenditures Change (TTM) |
6.97 % |
3.32 % |
-0.22 % |
0.34 % |
-1.88 % |
| Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 806 |
# 749 |
# 1305 |
# 1640 |
# 2332 |
| Cumulative Capital Expenditures growth
Comment |
Although Abbott Laboratories's Annual Capital Expenditures growth year on year were below company's average 19.57% , Capital Expenditures announced in the Jun 30 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 10.65% year on year, from 1.49% in Mar 31 2023.
In the Healthcare sector 119 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 857 to 902. |
| Capital Expenditures TTM Q/Q Growth Statistics |
| High |
Average |
Low |
697.91 % |
19.57 % |
-36.22 % |
|
|
|
|
|
| Capital Expenditures TTM Y/Y Growth Statistics |
| High |
Average |
Low |
697.91 % |
19.57 % |
-36.22 % |
|
|
|
| Capital Expenditures TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 33 |
| Sector |
# 104 |
| S&P 500 |
# 806 |
|
| Cumulative Capital Expenditures growth
Comment |
Although Abbott Laboratories's Annual Capital Expenditures growth year on year were below company's average 19.57% , Capital Expenditures announced in the Jun 30 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 10.65% year on year, from 1.49% in Mar 31 2023.
In the Healthcare sector 119 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 857 to 902. |
| Capital Expenditures TTM Q/Q Growth Statistics |
| High |
Average |
Low |
697.91 % |
19.57 % |
-36.22 % |
|
|
|
| Capital Expenditures TTM Y/Y Growth Statistics |
| High |
Average |
Low |
697.91 % |
19.57 % |
-36.22 % |
|
|
|
| Capital Expenditures TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 33 |
| Sector |
# 104 |
| S&P 500 |
# 806 |
|
54.90%